Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1991-09-27
1994-02-15
Waddell, Frederick E.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514564, 514565, 514921, 514929, 514561, 514567, 514562, 514419, A61K 31195
Patent
active
052867390
ABSTRACT:
An anti-hypotensive formulation comprising an essentially arginine-free or low arginine (less than about 0.1%, most preferably, about 0.01%) containing mixture of amino acids is provided. The invention in particular embodiments of the anti-hypotensive formulation includes ornithine, citrulline or both. A method for prophylaxis and treatment of systemic hypotension in an animal is provided. Most particularly, a method for treating hypotension caused by nitric oxide synthesis through administering a low or essentially arginine-free parenteral formulation to an animal, so as to reduce or eliminate nitric oxide synthesis is described. A method for treating an animal in septic shock is also disclosed, comprising administering to the animal an anti-hypotensive formulation comprising a mixture of amino acids, which is essentially arginine free. Prophylaxis or treatment of systemic hypotension, particularly that hypotension incident to chemotherapeutic treatment with biologic response modifiers, such as tumor necrosis factor or interleukin-1 or -2, may be accomplished through the administration of the defined anti-hypotensive formulations until physiologically acceptable systolic blood pressure levels are achieved in the animal. Treatment of an animal for septic shock induced by endotoxin may also be accomplished by administering to the animal the arginine-free formulations described.
REFERENCES:
patent: 3950529 (1976-04-01), Fischer et al.
patent: 4859452 (1989-08-01), Ajani et al.
patent: 4988724 (1991-01-01), Ajani et al.
patent: 5006559 (1991-04-01), Askanazi et al.
patent: 5028627 (1991-07-01), Kilbourn et al.
patent: 5036052 (1991-07-01), Ozeki et al.
patent: 5059712 (1991-10-01), Griffith
patent: 5132453 (1992-07-01), Griffith
patent: 5158883 (1992-10-01), Griffith
patent: 5162373 (1992-11-01), Ajani et al.
patent: 5189025 (1993-02-01), Ajani et al.
Moncada et al., "Nitric Oxide: Physiology, Pathophysiology, and Pharmacology," Pharmacological Reviews, 43(2):109-142, 1991, published in USA.
Moncada et al., "The L-Arginine: Nitric Oxide Pathway," Journal of Cardiovascular Pharmacology, 17(Suppl. 3):S1-S9, 1991, published in USA.
Parratt, J. R., and Stoclet, Jean-Claude, "Possible Role of Nitric Oxide in Refractory Hypotension Associated with Sepsis and Endotoxaemia and with Multiple Organ Failure," Applied Cardiopulmonary Pathophysiology, 4:143-149, 1991, published in USA.
Johnston, Jeff, "Molecular Science Sets Its Sights On Septic Shock," The Journal of NIH Research, 3:61-65, 1991, published in USA.
Moncada, S., and Higgs, E. A., "Endogenous Nitric Oxide: Physiology, Pathology and Clinical Relevance," European Journal of Clinical Investigation, 21:361-374, 1991, published in Europe.
Martin et al., "Selective Blockade of Endothelium-Dependent and Glyceryl Trinitrate-Induced Relaxation by Hemoglobin and by Methylene Blue in the Rabbit Aorta," The Journal of Pharmacology and Experimental Therapeutics, 232(3):708-716, 1985, published in USA.
Buga et al., "Endothelium-Derived Nitric Oxide Relaxes Nonvascular Smooth Muscle," European Journal of Pharmacology, 161:61-72, 1989, published in Europe.
Stueher et al., "Synthesis of Nitrogen Oxides from L-Arginine by Macrophage Cytosol: Requirement for Inducible and Constitutive Components," Biochemical and Biophysical Research Communications, 161(2):420-426, 1989, published in USA.
Aisaka et al., "N.sup.G Methylarginine, An Inhibitor of Endothelium-Derived Nitric Oxide Synthesis, Is A Potent Pressor Agent in The Guinea Pig: Does Nitric Oxide Regulate Blood Pressure In Vivo?", Biochemical and Biophysical Research Communications, 160(2):881-886, 1989, published in USA.
Torti et al., "A Macrophage Factor Inhibits Adipocyte Gene Expression: An in Vitro Model of Cachexia," Science, 229:867-871, 1985, published in USA.
Kilbourn et al., "Activated Macrophages Secrete a Soluble Factor That Inhibits Mitochondrial Respiration of Tumor Cells," The Journal of Immunology, 133(5):2577-2588, 1984, published in USA.
Vallance et al., "Effects of Endothelium-Derived Nitric Oxide on Peripheral Arteriolar Tone in Man," The Lancet, Ltd., 997-999, Oct. 1989, published in Europe.
Palmer et al., "Vascular Endothelial Cells Synthesize Nitric Oxide from L-Arginine," Nature, 333:664-666, 1988, published in Europe.
Old, Loyd J., "Tumor Necrosis Factor (TNF)," Science, 23:630-632, 1985, published in USA.
Yoshida and Kasama, "Biotransformation of Nitric Oxide," Enviornmental Health Perspectives, 78:201-206, 1987, published in USA.
Reif and Simmons, "Nitric Oxide Mediates Iron Release from Ferritin," Archives of Biochemistry and Biophysics, 283(2):537-541, 1990, published in USA.
Kruszyna et al., "Nitrite Conversion to Nitric Oxide in Red Cells and Its Stabilization as a Nitrosylated Valency Hybrid of Hemoglobin," The Journal of Pharmacology and Experimental Therapeutics, 241(1):307-313, 1987, published in USA.
Kosaka et al., "The Interaction Between Nitrogen Oxides and Hemoglobin and Endothelium-Derived Relaxing Factor," Free Radical Biology and Medicine, 7:653-658, 1989, published in USA.
Chevion et al., "Iron-Nitrosyl Bond configuration in Nitrosyl-Hemoproteins: A comparative EPR Study of Hemoglobin A and Hemoglobin Kansas," Israel Journal of Chemistry, 15:311-317, 1976, published in Israel.
Collier and Vallance, "Second Messenger Role for NO Widens to Nervous and Immune Systems," Trends in Pharmacological Sciences Including Toxicological Sciences, Elseview Science Publishers, Ltd., front page and pp. 428-431, 1989, published in United Kingdom.
Ignarro et al., "Endothelium-Derived Relaxing Factor Produced and Released from Artery and Vein is Nitric Oxide,"Proc. Natl. Acad. Sci. USA, 84:9265-9269, 1987, published in USA.
Murray et al., "Stabilization and Partial Characterization of Endothelium-Derived Relaxing Factor from Cultured Bovine Aortic Endothelial Cells," Biochemical and Biophysical Research Communications, 141(2):689-696, 1986, published in USA.
Marletta, Michael A., "Nitric Oxide: Biosynthesis and Biological Significance," name of publication unknown, Elseview Science Publishers, Ltd., pp. 448-493, 1989, published in United Kingdom.
Kilbourn et al., (1990), Journal Nat'l Cancer Inst., 82(9):772-776.
Kilbourn et al., (May 1990), Proc. Natl. Acad. Sci. USA, 87:3629-32.
Sakuma et al., (1988), Proc. Natl. Acad. Sci. USA, 85:8664-67.
Stuehr et al., (1989), J. Exp. Med., 169:1011-20.
Hibbs et al., (1988), Biochem. Biophys. Res. Comm., 157(1):87-94.
Stuehr et al., (1987), J. Immunology, 139:518-525.
Palmer et al., (1987), Nature, 327:542-526.
Natanson et al., (1989). J. Exp. Med., 169:823-832.
Starnes et al., (1988), J. Clin. Invest., 82(4):1321-25.
Nathan et al., (1990). Journal Natl Cancer Inst. (USA), 82(9):726-28.
Schmidt et al., (1988). European J. of Pharmacology, 154:213-216.
Griffith Owen W.
Gross Steven S.
Kilbourn Robert G.
Board of Regents University of Texas System
Criares T. J.
Waddell Frederick E.
LandOfFree
Parenteral formulations for the inhibition of systemic hypotensi does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Parenteral formulations for the inhibition of systemic hypotensi, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Parenteral formulations for the inhibition of systemic hypotensi will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1207206